← Back to Screener
Assertio Holdings, Inc. Common Stock (ASRT)
Price$18.14
Favorite Metrics
Price vs S&P 500 (26W)35.10%
Price vs S&P 500 (4W)25.21%
Market Capitalization$116.08M
All Metrics
P/CF (Annual)4.69x
Book Value / Share (Quarterly)$14.63
P/TBV (Annual)1.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.74%
Cash Flow / Share (Quarterly)$-4.39
Price vs S&P 500 (YTD)94.43%
Gross Margin (TTM)70.19%
Net Profit Margin (TTM)-25.59%
EPS (TTM)$-4.92
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$-4.92
Revenue Growth (5Y)2.23%
EPS (Annual)$-4.74
ROI (Annual)-22.83%
Gross Margin (Annual)70.19%
Net Profit Margin (5Y Avg)-38.43%
Cash / Share (Quarterly)$9.87
Revenue Growth QoQ (YoY)-57.92%
ROA (Last FY)-11.38%
Revenue Growth TTM (YoY)-5.00%
EBITD / Share (TTM)$0.05
ROE (5Y Avg)-48.68%
Operating Margin (TTM)-25.03%
Cash Flow / Share (Annual)$-4.39
P/B Ratio1.24x
P/B Ratio (Quarterly)0.62x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.22x
Net Interest Coverage (TTM)-222.43x
ROA (TTM)-10.59%
EV / EBITDA (TTM)404.95x
EPS Incl Extra (Annual)$-4.74
Current Ratio (Annual)1.70x
Quick Ratio (Quarterly)1.44x
3-Month Avg Trading Volume0.10M
52-Week Price Return93.24%
EV / Free Cash Flow (Annual)0.92x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$7.01
P/S Ratio (Annual)0.98x
Asset Turnover (Annual)0.44x
52-Week High$20.45
Operating Margin (5Y Avg)-35.52%
EPS Excl Extra (Annual)$-4.74
Tangible BV CAGR (5Y)-3.92%
26-Week Price Return43.85%
Quick Ratio (Annual)1.44x
13-Week Price Return76.40%
Total Debt / Equity (Annual)0.42x
Current Ratio (Quarterly)1.70x
Enterprise Value$144.972
Revenue / Share Growth (5Y)35.51%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)49.57%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)1.13x
Pretax Margin (Annual)-25.22%
Cash / Share (Annual)$9.87
3-Month Return Std Dev64.63%
Gross Margin (5Y Avg)79.18%
Net Income / Employee (TTM)$-1
ROE (Last FY)-32.33%
Net Interest Coverage (Annual)-134.98x
EPS Basic Excl Extra (Annual)$-4.74
P/FCF (TTM)3.86x
Receivables Turnover (TTM)1.36x
EV / Free Cash Flow (TTM)9.74x
Total Debt / Equity (Quarterly)0.42x
EPS Incl Extra (TTM)$-4.92
Receivables Turnover (Annual)1.36x
ROI (TTM)-21.78%
P/S Ratio (TTM)0.98x
Pretax Margin (5Y Avg)-38.02%
Revenue / Share (Annual)$18.54
Tangible BV / Share (Annual)$7.01
Free OCF CAGR (5Y)-21.57%
Price vs S&P 500 (52W)58.15%
Year-to-Date Return98.57%
5-Day Price Return-0.06%
EPS Normalized (Annual)$-4.74
ROA (5Y Avg)-21.75%
Net Profit Margin (Annual)-25.59%
Month-to-Date Return-5.51%
Cash Flow / Share (TTM)$-2.28
EBITD / Share (Annual)$0.02
Operating Margin (Annual)-25.03%
LT Debt / Equity (Annual)0.42x
P/CF (TTM)9.68x
ROI (5Y Avg)-37.53%
LT Debt / Equity (Quarterly)0.42x
EPS Basic Excl Extra (TTM)$-4.92
P/TBV (Quarterly)1.29x
P/B Ratio (Annual)0.62x
Inventory Turnover (TTM)1.14x
Pretax Margin (TTM)-25.22%
Book Value / Share (Annual)$14.63
Price vs S&P 500 (13W)73.53%
Beta0.43x
P/FCF (Annual)4.40x
Revenue / Share (TTM)$18.49
ROE (TTM)-30.26%
52-Week Low$8.55
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ASRTAssertio Holdings, Inc. Common Stock | 0.98x | -5.00% | 70.19% | — | $18.14 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Assertio Holdings is a specialty pharmaceutical company focused on neurology and pain management. It markets three FDA-approved products: Gralise for postherpetic neuralgia, CAMBIA for acute migraine treatment, and Zipsor for mild to moderate pain relief.